Zortea Karine, Franco Viviane C, Francesconi Lenise P, Cereser Keila M M, Lobato Maria Inês R, Belmonte-de-Abreu Paulo S
Schizophrenia Program, Hospital de Clínicas de Porto Alegre, Porto Alegre 90035-903, RS, Brazil.
Postgraduate Program in Medicine: Psychiatry, Universidade Federal do Rio Grande do Sul, Porto Alegre 90035-903, RS, Brazil.
Nutrients. 2016 Jan 29;8(2):73. doi: 10.3390/nu8020073.
Patients with schizophrenia (SZ) are generally overweight or obese and have several metabolic disorders. Additionally, such patients have a lower life expectancy and the main cause of their increased mortality is cardiovascular disease (CVD). The objective of this study was to determine the efficacy of resveratrol supplementation on serum glucose and CVD risk factors in individuals with SZ.
This is a four-week randomized, double-blind controlled trial (registration No.: NCT 02062190) in which 19 men with a diagnosis of SZ, aged 18 to 65, were assigned to either a resveratrol supplement group (200 mg/day) or a placebo group (200 mg/day). In short, we did not observe significant changes after resveratrol supplementation. In the placebo group, we found a significant increase in total cholesterol levels (p = 0.024) and in LDL-cholesterol (p = 0.002), as well as a decrease in body fat percentage (p = 0.038). The placebo group also showed an increase in triglycerides (9.19%) and a reduction in HDL-cholesterol (4.88%). In the resveratrol group, triglycerides decreased (7.64%).
In summary, oral resveratrol in reasonably low dosages (200 mg daily) brought no differences to body weight, waist circumference, glucose, and total cholesterol. It was possible to note that the lipid profile in the placebo group worsened and, although no significant differences were found, we can assume that resveratrol might prevent lipid profile damage and that the intervention affected the lipoprotein metabolism at various levels.
精神分裂症（SZ）患者通常超重或肥胖，并患有多种代谢紊乱。此外，这类患者预期寿命较低，其死亡率增加的主要原因是心血管疾病（CVD）。本研究的目的是确定补充白藜芦醇对SZ患者血清葡萄糖和CVD危险因素的疗效。
这是一项为期四周的随机双盲对照试验（注册号：NCT 02062190），19名年龄在18至65岁之间、诊断为SZ的男性被分为白藜芦醇补充组（200毫克/天）或安慰剂组（200毫克/天）。简而言之，补充白藜芦醇后我们未观察到显著变化。在安慰剂组中，我们发现总胆固醇水平（p = 0.024）和低密度脂蛋白胆固醇（p = 0.002）显著升高，以及体脂百分比降低（p = 0.038）。安慰剂组还显示甘油三酯升高（9.19%）和高密度脂蛋白胆固醇降低（4.88%）。在白藜芦醇组中，甘油三酯降低（7.64%）。
总之，口服合理低剂量（每日200毫克）的白藜芦醇对体重、腰围、血糖和总胆固醇没有差异。可以注意到安慰剂组的血脂状况恶化，尽管未发现显著差异，但我们可以假设白藜芦醇可能预防血脂状况损害，并且该干预在不同水平上影响脂蛋白代谢。
